White Papers
This report, the sixth in our Trinity Drug Index series, outlines key themes and emerging trends in the industry as we progress towards a new world of targeted and innovative products. We provide a comprehensive evaluation of the commercial performance over three years of novel drugs approved by the FDA in 2020, with commercial, therapeutic value and R&D investment scores for each. 2020 saw 58 unique drug and biologic approvals, of which the majority were Oncology (29%) followed by Neurology…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences for a virtual lunch and learn where Krista Perry—Partner & Head of Launch Excellence, Curt Staab—Head of Client Development and Tarra Maeshima—Director of New Products & Strategy will demonstrate Trinity Launch Accelerator.
Launch project management office (PMO) teams and/or dedicated project manager (PM) resources are critical to enabling Launch Excellence-and the best support a PM can have is a single-source-of-truth launch planning and management tool that enables the integration necessary and takes work off everyone’s plate.…
Watch Now
Blog
Published December 18, 2023
First, A Few Potentially Unsettling Truths
Adoption and adaptation to Generative AI (GenAI) is a strategic imperative for pharma commercial insights departments if they want to maintain and enhance their relevance, impact, and strategic value within their organizations.
Organizations are increasingly data-driven; market research teams that do not leverage AI will struggle to provide the timely, nuanced insights that modern pharma marketing organizations demand, diminishing their role in critical decision-making processes.
Top talent gravitates towards innovation. Departments that fail to…
Read Now
Briefs
Highlights from TGaS Advisors’ Fall Summit
How are Biopharmaceutical organizations evolving to develop capabilities and propel innovation for 2024 and beyond?
Executive leaders in Commercial Operations, Medical Affairs and Market Access are focused on making informed decisions to propel the evolution of their organizations in this rapidly changing global economy. As you strategize to accelerate optimizing structure, talent and capabilities to excel in the future, this Advisory Brief brings you critical insights gleaned from the recent TGaS Advisors’ Fall Summit.…
Read Now
White Papers
Cell therapies are becoming increasingly incorporated as late-line standards of care across relapsed/refractory oncology indications, with an expanding ability to improve outcomes for a diverse set of tumors and patient subgroups. As the next frontier of personalized and precision medicine continues to grow, Natural Killer (NK) cell therapies offer the potential to penetrate untapped needs across a variety of cancers. However, enthusiasm surrounding the opportunity offered by NK-based technologies has fluctuated over recent years. Several large pharma leaders have made…
Read Now
Blog
Published December 7, 2023
Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both academics and the life sciences industry, including manufacturers, regulatory leaders and health economists, to consider the latest challenges and opportunities being addressed by health economics and outcomes research. Topics included Joint Clinical Assessments (JCAs), access to innovative therapies, environmental…
Read Now
Blog
Published November 17, 2023
Introduction
The Trinity team recently attended the Milken Institute’s 2023 Future of Health Summit in Washington, DC. Its theme was “Closing the Gap” in healthcare – as chronic disease becomes more prevalent worldwide and the average life expectancy in the US declines to its lowest level since the early 1990’s, what can be done? The sessions explored how industry leaders, government officials, nonprofits, and patients can work together to reverse the declining and diverging metrics we see in healthcare outcomes…
Read Now
Scientific Publications
Implications of the Implementation of the Joint Committee Assessment on Launch Planning for Medical Technologies in Europe
Acosta Luis S1, O’Hara M2, Yeh M2
1Trinity Partners, LLC, London, UK, 2Trinity Life Sciences, Waltham, MA, USA
The EU-wide Joint Clinical Assessment (JCA) is set to be operational from January 2025. The Trinity team reviewed the available literature and summarized the JCA implications for medical device launch planning and evidence-generation requirements, including the central role that HEOR expertise across different geographies will…
Read Now
Blog
Published November 7, 2023
In August 2023, the Colombian government published a new pricing policy outlining that the list price of new medicines in Colombia will be established based on their therapeutic value category, resulting from an assessment conducted by the Instituto de Evaluation Tecnológica en Salud (IETS). The outcomes of the therapeutic assessment are then reported to the National Commission for Prices of Medicines and Medical Devices (CNPMDM), which is responsible for setting the list price of the new drugs. Up until now,…
Read Now
Webinars
Available On Demand
Watched our AIML 101 webinar and ready to learn more? Trinity Life Sciences is excited to continue the conversation with our next webinar, which will dive deeper into how pharma companies can move beyond the hype to unlock the value of Generative AI (GenAI).
Join Trinity experts, Steve Laux, VP of Commercial Insights & Advanced Analytics, Nabha Subramanya, VP of Data Science and Patrick Waring, Director of New Products & Strategy, as they sift through all the noise surrounding GenAI and share…
Watch Now
